Future Fund LLC Acquires 28,433 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Future Fund LLC lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,973 shares of the biopharmaceutical company’s stock after buying an additional 28,433 shares during the period. Future Fund LLC owned about 0.06% of Catalyst Pharmaceuticals worth $1,750,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Rothschild Investment LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,520 shares during the last quarter. Clearstead Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 192.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the last quarter. Larson Financial Group LLC grew its holdings in Catalyst Pharmaceuticals by 552.7% during the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,564 shares during the last quarter. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at about $39,000. Finally, Quarry LP bought a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at about $40,000. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $35.00 to $31.50 in a report on Thursday. Finally, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $31.23 on Friday. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 0.95 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The firm has a 50-day moving average of $27.62 and a two-hundred day moving average of $25.03.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).